Analysts have been eager to weigh in on the Healthcare sector with new ratings on Actinium Pharmaceuticals (ATNM – Research Report) and Inovio Pharmaceuticals (INO – Research Report).
Actinium Pharmaceuticals (ATNM)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals today and set a price target of $50.00. The company’s shares closed last Thursday at $6.45, close to its 52-week low of $5.87.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $28.12, implying a 324.8% upside from current levels. In a report released yesterday, HSBC also initiated coverage with a Buy rating on the stock with a $11.60 price target.
See Insiders’ Hot Stocks on TipRanks >>
Inovio Pharmaceuticals (INO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals. The company’s shares closed last Thursday at $0.45, close to its 52-week low of $0.38.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Inovio Pharmaceuticals has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATNM:
